Pharmacy News

Novartis’ Cosentyx wins NICE backing for non-radiographic axial spondyloarthritis

Novartis’ Cosentyx has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA).

NICE has recommended Cosentyx (secukinumab) as an option for the treatment of active nr-axSpA with objective signs of inflammation that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs) in adults.

The IL-17A inhibitor is recommended only if tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough.

“Axial SpA is a painful and progressive long-term condition affecting approximately one in 200 people in the UK,” said Dale Webb, chief executive of the UK’s National Axial Spondyloarthritis Society (NASS).

“Axial SpA can result in long-term pain, impaired mobility and fatigue. Earlier diagnosis and treatment can have a significant impact on the progression of the condition and people’s long-term outcomes, and NASS welcomes new treatment options,” he added.

The recommendation is based on data from the Phase III PREVENT study, in which 40.8% of nr-axSpA patient treated with Cosentyx 150mg showed significant relief of symptoms compared to 28% in the placebo group.

In addition, statistically significant improvements across secondary endpoints were also observed, including pain and fatigue, disease burden and health-related quality of life.

“The decision from NICE in nr-axSpA comes on the heels of the Scottish Medicines Consortium (SMC) approval and means secukinumab is now recommended as a much-needed additional treatment option for patients with this debilitating condition in England, Scotland and Wales,” said Caitriona Walsh, regional partnership business unit head, Novartis UK.

“The symptoms of nr-axSpA often mean that patients require both practical and emotional support when undergoing treatment and this is available through the Novartis You First patient support programme,” she added.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Ad Block Detected

Welcome to Mediexpose, Please support our journalism by allowing ads. With support from readers like you, we can continue to deliver the best. You can support us free by simply allowing ads.